Morgan Stanley’s BioVie BIVI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.17M Buy
605,471
+530,250
+705% +$833K ﹤0.01% 5131
2026
Q1
$105K Buy
75,221
+14,999
+25% +$19.3K ﹤0.01% 6134
2025
Q4
$69.9K Buy
60,222
+29,925
+99% +$48.2K ﹤0.01% 6326
2025
Q3
$57.6K Buy
30,297
+29,744
+5,379% +$121K ﹤0.01% 6357
2025
Q2
$5.11K Buy
553
+67
+14% +$662 ﹤0.01% 7026
2025
Q1
$4.76K Sell
486
-2,027
-81% -$32.4K ﹤0.01% 7005
2024
Q4
$50.3K Buy
2,513
+2,237
+811% +$53.9K ﹤0.01% 6287
2024
Q3
$3.31K Buy
276
+152
+123% +$4.85K ﹤0.01% 7020
2024
Q2
$4.95K Sell
124
-122
-50% -$5.84K ﹤0.01% 6854
2024
Q1
$13K Sell
246
-584
-70% -$59.9K ﹤0.01% 6605
2023
Q4
$105K Buy
830
+277
+50% +$83.2K ﹤0.01% 5929
2023
Q3
$189K Buy
553
+185
+50% +$72.3K ﹤0.01% 5605
2023
Q2
$159K Buy
368
+94
+34% +$63.3K ﹤0.01% 5740
2023
Q1
$221K Buy
274
+51
+23% +$33.8K ﹤0.01% 5669
2022
Q4
$174K Buy
223
+202
+962% +$109K ﹤0.01% 5724
2022
Q3
$5K Buy
21
+6
+40% +$1.43K ﹤0.01% 7241
2022
Q2
$2K Hold
15
﹤0.01% 7569
2022
Q1
$7K Hold
15
﹤0.01% 7492
2021
Q4
$7K Buy
15
+14
+1,400% +$8.09K ﹤0.01% 7561
2021
Q3
$1K Buy
+1
New +$1.07K ﹤0.01% 7753
2021
Q2
Hold
0
7588
2021
Q1
Sell
-8
Closed -$22.8K 7325
2020
Q4
$14K Hold
8
﹤0.01% 6542
2020
Q3
$8K Buy
+8
New +$7.6K ﹤0.01% 6324

Other funds holding BIVI

Morgan Stanley's BIVI Position: Q2 2026 in Review

Morgan Stanley increased its BioVie (BIVI) stake by 705% in Q2 2026, buying an estimated $833K and bringing the position to 605,471 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #5131.

Morgan Stanley first reported a position in BIVI in Q3 2020 and has held it in 22 quarters since. 35 funds tracked by Wall St. Rank hold BIVI as of Q2 2026.

  • Morgan Stanley held 605,471 shares of BioVie worth $1.17M as of Q2 2026.
  • Morgan Stanley bought 530,250 BioVie shares in Q2 2026, an estimated $833K.
  • BioVie made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5131 holding.
  • Morgan Stanley first reported a position in BioVie in Q3 2020 and has held it in 22 quarters since.
  • 35 funds tracked by Wall St. Rank held BioVie as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.